Protara Therapeutics Inc Financials
This page shows Protara Therapeutics Inc (TARA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 14 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Development spending is being funded mainly by new equity capital, while cash usage closely tracks accounting losses.
FY2025's-$57.4M net loss and-$56.4M operating cash outflow were nearly identical, showing that the reported loss is mostly real cash consumed by operations rather than an accrual artifact. With no reported long-term debt and shares outstanding rising from 35.0M to 53.6M, funding is coming primarily from issuing stock rather than borrowing.
The burn accelerated mainly through research spending: R&D reached
Year-end cash fell to
Financial Health Signals
Protara Therapeutics Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Protara Therapeutics Inc passes 1 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
Protara Therapeutics Inc reported a net loss of $57.4M while operations used $56.4M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Protara Therapeutics Inc's EBITDA was -$64.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 31.5% from the prior year.
Protara Therapeutics Inc reported -$57.4M in net income in fiscal year 2025. This represents a decrease of 28.7% from the prior year.
Protara Therapeutics Inc earned -$1.34 per diluted share (EPS) in fiscal year 2025.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Protara Therapeutics Inc recorded an outflow of $56.5M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents a decrease of 57.4% from the prior year.
Protara Therapeutics Inc held $49.7M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
Protara Therapeutics Inc's ROE was -29.2% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 2.5 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
Protara Therapeutics Inc invested $42.6M in research and development in fiscal year 2025. This represents an increase of 34.5% from the prior year.
Protara Therapeutics Inc invested $94K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 49.2% from the prior year.
Not reported for fiscal year 2025.
TARA Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $2.9M | N/A | N/A |
| R&D Expenses | N/A | $42.6M+34.5% | $31.7M+26.9% | $25.0M+48.7% | $16.8M-20.3% | $21.1M+76.0% | $12.0M+209.0% | $3.9M-67.3% | $11.8M-45.4% | $21.7M+14.9% | $18.9M+52.4% | $12.4M+92.5% | $6.4M+61.0% | $4.0M-32.4% | $5.9M |
| SG&A Expenses | N/A | $21.9M+25.6% | $17.4M-6.3% | $18.6M-10.2% | $20.7M-21.5% | $26.4M+17.5% | $22.5M+468.4% | $4.0M-58.5% | $9.5M+9.8% | $8.7M-11.8% | $9.8M+15.9% | $8.5M+107.3% | $4.1M+30.9% | $3.1M+49.7% | $2.1M |
| Operating Income | N/A | -$64.5M-31.3% | -$49.2M-12.7% | -$43.6M+35.0% | -$67.1M-41.2% | -$47.5M-37.9% | -$34.4M | N/A | -$21.4M+29.6% | -$30.4M-5.8% | -$28.7M-37.5% | -$20.9M-175.3% | -$7.6M-6.4% | -$7.1M+10.9% | -$8.0M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | $0-100.0% | $34K | N/A | N/A | N/A | N/A | N/A | $857K-0.5% | $861K | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -$110K-219.6% | $92K+165.7% | -$140K |
| Net Income | N/A | -$57.4M-28.7% | -$44.6M-10.4% | -$40.4M+38.7% | -$66.0M-39.6% | -$47.3M-39.1% | -$34.0M | N/A | -$20.7M+30.8% | -$30.0M-5.0% | -$28.5M-33.4% | -$21.4M-539.6% | -$3.3M+57.8% | -$7.9M+0.7% | -$8.0M |
| EPS (Diluted) | — | -$1.34 | -$2.17 | -$3.57+39.1% | -$5.86-39.2% | -$4.21 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
TARA Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $209.5M+15.4% | $181.5M+129.8% | $79.0M-30.3% | $113.3M-34.4% | $172.6M-15.0% | $203.2M+16511.4% | $1.2M-94.8% | $23.5M-46.5% | $44.0M+1.1% | $43.5M-35.6% | $67.5M-20.4% | $84.8M+1398.5% | $5.7M | N/A |
| Current Assets | $159.5M-7.3% | $172.2M+150.6% | $68.7M-20.2% | $86.1M-7.5% | $93.1M-45.0% | $169.4M+22077.4% | $764K-96.7% | $23.2M-46.6% | $43.5M+1.7% | $42.8M-35.8% | $66.6M-21.3% | $84.6M+1487.3% | $5.3M | N/A |
| Cash & Equivalents | $49.7M-69.5% | $162.8M+311.3% | $39.6M+64.1% | $24.1M-32.5% | $35.7M-78.8% | $168.6M+29793.3% | $564K-97.1% | $19.4M-8.5% | $21.2M-41.8% | $36.4M-9.1% | $40.0M-41.8% | $68.8M+2364.7% | $2.8M+15.9% | $2.4M |
| Goodwill | N/A | N/A | N/A | N/A | $29.5M0.0% | $29.5M | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $13.1M-8.8% | $14.3M+34.7% | $10.6M-5.1% | $11.2M+4.9% | $10.7M+172.9% | $3.9M+16.8% | $3.4M-82.1% | $18.7M+102.8% | $9.2M+81.9% | $5.1M+22.9% | $4.1M+76.8% | $2.3M-97.8% | $106.2M | N/A |
| Current Liabilities | $10.9M-0.2% | $11.0M+78.3% | $6.1M+7.1% | $5.7M+33.6% | $4.3M+47.4% | $2.9M-13.0% | $3.4M+8.9% | $3.1M-66.7% | $9.2M+81.9% | $5.1M+22.9% | $4.1M+76.8% | $2.3M-76.1% | $9.8M | N/A |
| Total Equity | $196.4M+17.5% | $167.1M+144.6% | $68.3M-33.1% | $102.1M-37.0% | $161.9M-18.7% | $199.2M+9462.9% | -$2.1M-144.5% | $4.8M-86.2% | $34.7M-9.6% | $38.4M-39.4% | $63.4M-23.1% | $82.5M+182.0% | -$100.5M-16.0% | -$86.7M |
| Retained Earnings | -$302.4M-23.4% | -$245.0M-22.3% | -$200.4M-25.3% | -$160.0M-70.2% | -$94.0M-101.1% | -$46.8M-265.8% | -$12.8M+93.9% | -$210.5M-10.9% | -$189.7M-18.8% | -$159.8M-21.7% | -$131.3M-19.5% | -$109.9M-9.3% | -$100.5M | N/A |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Long-Term Debt.
TARA Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$66.1M | -$56.4M-57.4% | -$35.8M+4.7% | -$37.6M-42.0% | -$26.5M+23.3% | -$34.5M-47.4% | -$23.4M-367.1% | -$5.0M+78.4% | -$23.2M-3.9% | -$22.4M+5.6% | -$23.7M-34.8% | -$17.6M-75.8% | -$10.0M-50.1% | -$6.7M+19.2% | -$8.2M |
| Capital Expenditures | N/A | $94K+49.2% | $63K+40.0% | $45K-62.5% | $120K-79.9% | $596K-32.6% | $884K+86.1% | $475K+299.2% | $119K+240.0% | $35K-87.1% | $271K+36.9% | $198K+288.2% | $51K+410.0% | $10K-85.1% | $67K |
| Free Cash Flow | N/A | -$56.5M-57.4% | -$35.9M+4.6% | -$37.6M-41.5% | -$26.6M+24.3% | -$35.1M-44.5% | -$24.3M-342.8% | -$5.5M+76.5% | -$23.4M-4.3% | -$22.4M+6.6% | -$24.0M-34.9% | -$17.8M-76.9% | -$10.0M-50.6% | -$6.7M+19.7% | -$8.3M |
| Investing Cash Flow | -$30.4M | -$139.5M-828.2% | $19.2M-63.9% | $53.1M+255.2% | $14.9M+115.2% | -$98.2M-3563.6% | $2.8M+696.8% | -$475K-102.6% | $18.4M+214.5% | -$16.1M-180.8% | $19.9M+275.8% | -$11.3M | N/A | N/A | N/A |
| Financing Cash Flow | $82.1M | $82.7M-40.9% | $139.9M+153797.8% | -$91K-1.1% | -$90K+60.5% | -$228K-100.1% | $189.4M+37780.2% | $500K-83.2% | $3.0M-87.0% | $23.0M+10981.3% | $208K+27.6% | $163K | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | $91K+1.1% | $90K-60.5% | $228K | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Dividends Paid.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
TARA Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -257.1% | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -113.4% | N/A | N/A |
| Return on Equity | -29.2%-2.5pp | -26.7%+32.4pp | -59.1%+5.5pp | -64.6%-35.4pp | -29.2%-12.1pp | -17.1% | N/A | -433.8%-347.6pp | -86.3%-12.0pp | -74.2%-40.5pp | -33.7%-29.7pp | -4.0% | N/A | N/A |
| Return on Assets | -27.4%-2.8pp | -24.6%+26.6pp | -51.2%+7.1pp | -58.2%-30.8pp | -27.4%-10.7pp | -16.7% | N/A | -88.1%-20.0pp | -68.1%-2.6pp | -65.5%-33.9pp | -31.6%-27.7pp | -3.9%+135.9pp | -139.8% | N/A |
| Current Ratio | 14.58-1.1x | 15.71+4.5x | 11.17-3.8x | 15.01-6.7x | 21.66-36.5x | 58.13+57.9x | 0.23-7.3x | 7.55+2.8x | 4.71-3.7x | 8.42-7.7x | 16.12-20.1x | 36.19+35.6x | 0.55 | N/A |
| Debt-to-Equity | 0.070.0x | 0.09-0.1x | 0.160.0x | 0.110.0x | 0.070.0x | 0.02 | N/A | 3.92+3.7x | 0.27+0.1x | 0.13+0.1x | 0.070.0x | 0.03 | N/A | N/A |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -340.6% | N/A | N/A |
Not reported in any period shown, so not listed: Gross Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Protara Therapeutics Inc Ranks
Frequently Asked Questions
Is Protara Therapeutics Inc profitable?
No, Protara Therapeutics Inc (TARA) reported a net income of -$57.4M in fiscal year 2025.
What is Protara Therapeutics Inc's EBITDA?
Protara Therapeutics Inc (TARA) had EBITDA of -$64.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Protara Therapeutics Inc's return on equity (ROE)?
Protara Therapeutics Inc (TARA) has a return on equity of -29.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Protara Therapeutics Inc's free cash flow?
Protara Therapeutics Inc (TARA) recorded an outflow of $56.5M in free cash flow during fiscal year 2025. This represents a -57.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Protara Therapeutics Inc's operating cash flow?
Protara Therapeutics Inc (TARA) recorded an outflow of $56.4M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Protara Therapeutics Inc's total assets?
Protara Therapeutics Inc (TARA) had $209.5M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Protara Therapeutics Inc's capital expenditures?
Protara Therapeutics Inc (TARA) invested $94K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Protara Therapeutics Inc spend on research and development?
Protara Therapeutics Inc (TARA) invested $42.6M in research and development during fiscal year 2025.
What is Protara Therapeutics Inc's current ratio?
Protara Therapeutics Inc (TARA) had a current ratio of 14.58 as of fiscal year 2025, which is generally considered healthy.
What is Protara Therapeutics Inc's debt-to-equity ratio?
Protara Therapeutics Inc (TARA) had a debt-to-equity ratio of 0.07 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Protara Therapeutics Inc's return on assets (ROA)?
Protara Therapeutics Inc (TARA) had a return on assets of -27.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Protara Therapeutics Inc's cash runway?
Based on fiscal year 2025 data, Protara Therapeutics Inc (TARA) had $49.7M in cash against an annual operating cash burn of $56.4M. This gives an estimated cash runway of approximately 11 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Protara Therapeutics Inc's Piotroski F-Score?
Protara Therapeutics Inc (TARA) has a Piotroski F-Score of 1 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Protara Therapeutics Inc's earnings high quality?
Protara Therapeutics Inc (TARA) reported a net loss of $57.4M while operations used $56.4M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.